Piper Jaffray Cuts Price Target on Orexigen Therapeutics (OREX) to $5 Following 4Q Results
Tweet Send to a Friend
Piper Jaffray maintained an Overweight rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $5.00 (from $11.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
